The BEAM-BD trial, as presented in the New England Journal of Medicine in 2023, was a multisite, double-blind, randomized, placebo-controlled trial with the objective of comparing the maintenance of treatment with adjunctive escitalopram or bupropion XL versus discontinuation of antidepressant … Read More
depression
ESCAPE-TRD Trial: Esketamine in Depression
The ESCAPE-TRD trial, as reported in the New England Journal of Medicine in 2023, stands as a significant landmark in the ongoing quest to improve treatments for treatment-resistant depression (TRD). This trial assessed the efficacy and safety of esketamine nasal … Read More
VITAL-DEP Trial: vitamin D and omega-3 FA for depression
VITAL-DEP Trial Summary The VITAL-DEP trial aimed to investigate whether long-term supplementation with vitamin D3 could prevent depression in the general adult population. The study included 18,353 adults aged 50 years or older without depression or clinically relevant depressive symptoms … Read More
ELEKT-D Trial: Ketamine vs. ECT for Treatment-Resistant Major Depression
ELEKT-D Trial: Ketamine vs. ECT for Treatment-Resistant Major Depression Introduction:The groundbreaking ELEKT-D Trial sought to compare the efficacy of electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine for the treatment of patients with treatment-resistant major depression. This study aimed to determine … Read More
ANTLER Trial: Antidepressants in Primary care
2021 ANTLER TRIAL Maintenance or discontinuation of antidepressants in primary care Multicenter, randomized, double-blind trial M Objective: To assess the effects of maintenance antidepressant therapy, as compared with discontinuation of treatment, in patients taking antidepressants 478 patients Inclusion criteria: … Read More
PRIME Care Trial Summary: Pharmacogenomic Testing for Drug-Gene Interactions in Depression Treatment
2022 PRIME CARE TRIAL Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection in Major Depressive Disorder Randomised, pragmatic, clinical trial Objective: To assess if pharmacogenomic testing for drug-gene interactions affects the selection of antidepressant medication and response in … Read More